EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase III)Multizentrische Studie

Perioperative Enfortumab Vedotin and Pembrolizumab in Bladder Cancer

Christof Vulsteke, Nabil Adra iD, Pongwut Danchaivijitr, Maksym Sabadash, Alejo Rodriguez-Vida, Zhentao Zhang, Vagif Atduev, Y Emre Göger, Steffen Rausch, Seok-Ho Kang, Yohann Loriot, Jens Bedke iD und 15 weitere

New England Journal of Medicine · 02.04.2026 · 394 (13) · 1257-1269

DOI: 10.1056/nejmoa2511674 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift New England Journal of Medicine, erschienen am 02.04.2026. Verfasst von Christof Vulsteke und 26 weiteren Autor:innen. Beteiligte Einrichtung: Integrated Cancer Center Ghent, AZ Maria Middelares, Ghent, Belgium. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Antibodies, Monoclonal, Humanized, Antineoplastic Combined Chemotherapy Protocols, Immunoconjugates. Die Arbeit wurde bisher 144-mal zitiert (Crossref) und nennt 24 Literaturangaben. Gefördert von: Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, MonoclonalAntibodies, Monoclonal, HumanizedAntineoplastic Combined Chemotherapy ProtocolsImmunoconjugatesUrinary Bladder NeoplasmsAgedAged, 80 and overFemaleHumansMaleMiddle AgedChemotherapy, AdjuvantCystectomyKaplan-Meier EstimateNeoadjuvant TherapyNeoplasm InvasivenessPerioperative CareLymph Node ExcisionProgression-Free SurvivalPathologic Complete ResponseUrinary BladderFollow-Up Studies

Substanzen

Antibodies, MonoclonalAntibodies, Monoclonal, Humanizedenfortumab vedotinImmunoconjugatespembrolizumab

Autor:innen und Institutionen

  • Integrated Cancer Center Ghent, AZ Maria Middelares, Ghent, Belgium.
  • Center for Oncologic Research, Antwerp University, Antwerp, Belgium.
  • Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis.
  • Faculty of Medicine, Siriraj Hospital, Mahidol University, Bangkok, Thailand.
  • Lviv State Regional Oncological Center, Lviv, Ukraine.
  • Hospital del Mar, Barcelona.

ORCID-Profile: Nabil Adra, Jens Bedke

Förderung

  • Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA

Zitieren

APA

Vulsteke, C., Adra, N., Danchaivijitr, P., Sabadash, M., Rodriguez-Vida, A., Zhang, Z., Atduev, V., Göger, Y. E., Rausch, S., Kang, S. H., Loriot, Y., Bedke, J., Galsky, M. D., O'Donnell, P. H., von Amsberg, G., Alimohamed, N., Sulimka, G., Gupta, S., Paramonov, V., …, & KEYNOTE-905/EV-303 Investigators (2026). Perioperative Enfortumab Vedotin and Pembrolizumab in Bladder Cancer. New England Journal of Medicine, 394(13), 1257-1269. https://doi.org/10.1056/nejmoa2511674

Vancouver

Vulsteke C, Adra N, Danchaivijitr P, Sabadash M, Rodriguez-Vida A, Zhang Z, et al. Perioperative Enfortumab Vedotin and Pembrolizumab in Bladder Cancer. New England Journal of Medicine. 2026;394(13):1257-1269. doi:10.1056/nejmoa2511674

BibTeX
@article{Vulsteke2026,
  author = {Vulsteke, Christof and Adra, Nabil and Danchaivijitr, Pongwut and Sabadash, Maksym and Rodriguez-Vida, Alejo and Zhang, Zhentao and Atduev, Vagif and Göger, Y Emre and Rausch, Steffen and Kang, Seok-Ho and Loriot, Yohann and Bedke, Jens and Galsky, Matthew D and O'Donnell, Peter H and von Amsberg, Gunhild and Alimohamed, Nimira and Sulimka, Grzegorz and Gupta, Shilpa and Paramonov, Viktor and Nakane, Keita and Mihm, Michael and Meng, Changting and Huang, Caizhi David and Ramamurthy, Chethan and Homet Moreno, Blanca and Ullén, Anders and KEYNOTE-905/EV-303 Investigators, KEYNOTE-905/EV-303 Investigators},
  title = {Perioperative Enfortumab Vedotin and Pembrolizumab in Bladder Cancer},
  journal = {New England Journal of Medicine},
  year = {2026},
  volume = {394},
  number = {13},
  pages = {1257--1269},
  doi = {10.1056/nejmoa2511674}
}
Kostenlos starten →